Abstract 6878: Ag5: a novel quantum cluster therapy targeting mitochondria and antioxidant systems in glioblastoma
Abstract Despite extensive efforts from drug developers, physicians, and patients, the prognosis for glioblastoma (GBM) remains one of the poorest in adult oncology. Current oncology drug development often revisits established technologies, with few truly novel treatments emerging to tackle challenging diseases like GBM. ARJUNA Therapeutics is breaking new ground with quantum cluster technology, creating a unique family of small molecules. The first of these, Ag5, consists of five silver atoms (a quantum cluster) with demonstrated drug-like qualities, including the ability to cross the blood-brain barrier. Ag5 penetrates cells and specifically catalyzes the irreversible inactivation of both glutathione and thioredoxin antioxidant systems in cancer cells, rapidly depleting mitochondrial glutathione and inducing cell death with minimal off-target effects at therapeutic doses. In collaboration with ARJUNA, the Laboratory for Precision Cancer Medicine at KU Leuven, Belgium, screened 20 patient-derived glioma stem cell lines from adult GBM tumors. Ag5 demonstrated cell-killing effectiveness at submicromolar concentrations in approximately 50% of these models, showing activity in both newly diagnosed and recurrent tumor models, as well as in cells from both the core and infiltrating regions. Importantly, tumor cell lines taken from individual patients at various disease stages retained their Ag5 sensitivity, even as they acquired resistance to radiotherapy and/or TMZ. Biomarkers defining sensitivity and resistance to Ag5 in patient-derived GBM lines have been identified, supported by promising preclinical in vivo data. Ag5 has the potential to benefit a significant proportion of GBM patients. A clinical phase 0 neuro-oncology trial at University Hospitals Leuven, Belgium, is planned to test both the biomarker and therapeutic hypothesis for Ag5 in adult GBM patients. Citation Format: Jayesh Telang, Marleen Derweduwe, Vanesa Porto, Blanca Dominguez, Ross Breckenridge, Martin Treder, Fernando Dominguez, Annelies Claeys, Isabel Aguirre Alcolea, Frederik De Smet. Ag5: a novel quantum cluster therapy targeting mitochondria and antioxidant systems in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6878.
Authors
- Fernando Domı́nguez (ORCID: https://orcid.org/0000-0002-5003-4335)
- Blanca Domínguez (ORCID: https://orcid.org/0000-0003-4083-9049)
- Frederik De Smet (ORCID: https://orcid.org/0000-0002-6669-3335)
- Marleen Derweduwe (ORCID: https://orcid.org/0000-0002-4960-4847)
- Martin Treder
- Jayesh Telang
- Ross Breckenridge
- Vanesa Porto
- Annelies Claeys
- Isabel Aguirre Alcolea
Institutions
- Universidade de Santiago de Compostela (ES)
- KU Leuven (BE)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1158/1538-7445.am2025-6878
- Primary Topic
- Nanocluster Synthesis and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00